# Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure

> **NCT05949801** · PHASE3 · COMPLETED · sponsor: **Zensun Sci. & Tech. Co., Ltd.** · enrollment: 202 (actual)

## Conditions studied

- Chronic Systolic Heart Failure

## Interventions

- **DRUG:** Neucardin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05949801
- **Lead sponsor:** Zensun Sci. & Tech. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-13
- **Primary completion:** 2024-08-30
- **Final completion:** 2024-10-14
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2025-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05949801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05949801, "Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05949801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*